Market Cap
$78.1B
REGN
REGENERON PHARMACEUTICALS, INC.
$735.20 ▲ +0.05%
Prev close $734.81Market cap$78.1B
ConsensusBuy
12-mo target$853.19 (+16.0%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)35 New Institutional Positions15 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on REGN right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Buy (68%)
Inst. Holders
50 funds
Inst. Value
$44.5B
Inst. Activity
35 buys / 15 sells
Insider Activity
$0.00 buy / $4.0M sell
Insider Net $
-$4.0M
Social Sentiment
67° Warm
SEC Reports
14
Press Releases
12
Congressional
4 trades
Price chart 30d -12.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 fda
Oct 1, 2026 SEC Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is
Argus Research double upgrade: Hold → Buy
ANALYST-UPGRADE — Impact 4/10
Sep 3, 2026 Insider
McCourt Marion sold 1,131 shares
EVP Commercial @ $857.39 ($969.7K)
Sep 2, 2026 Insider
McCourt Marion sold 1,215 shares
EVP Commercial @ $850.00 ($1.0M)
Sep 2, 2026 Insider
Guarini Kathryn acquired via exercise 400 shares
Director @ $719.37 ($287.7K)
Aug 26, 2026 Event
Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01
Class II: Lack of Assurance of Sterility
Aug 24, 2026 Event
Aug 20, 2026 Press The United States of America et al v. Regeneron Pharmaceuticals, Inc. et al
Court ruling (mad) — Docket: 1:20-cv-11401
No summary provided
Impact 5/10
Analyst ratings buy % -10.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
68% rate it Buy or better · 38 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | Jefferies | MAINTAIN | Buy | 53% |
| Oct 1, 2026 | Argus Research | UPGRADE | Buy | 54% |
| Sep 29, 2026 | RBC Capital | REITERATE | Sector Perform | 55% |
| Sep 10, 2026 | HSBC | MAINTAIN | Buy | 55% |
| Aug 17, 2026 | Leerink Partners | MAINTAIN | Market Perform | 49% |
| Aug 3, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Aug 3, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Jul 31, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Jul 31, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Jul 31, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 18 | 12 | 0 | 0 | 68% | |
| Aug 1, 2026 | 8 | 18 | 11 | 0 | 0 | 70% | |
| Jul 1, 2026 | 9 | 18 | 11 | 0 | 0 | 71% | |
| Jun 1, 2026 | 9 | 18 | 11 | 0 | 0 | 71% | |
| May 1, 2026 | 11 | 19 | 8 | 0 | 0 | 79% | |
| Apr 1, 2026 | 11 | 19 | 8 | 0 | 0 | 79% | |
| Mar 1, 2026 | 11 | 16 | 9 | 0 | 0 | 75% | |
| Feb 1, 2026 | 11 | 16 | 9 | 0 | 0 | 75% |
Price targets
Where 26 covering analysts think REGN trades over the next 12 months.
$853.19 +16.0% upside Buy
Current$735.20 Low$730.00 Median$857.00 High$1,030.00 26 analysts
$730.00$1,030.00
Analyst rating Buy· 1.9/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 6 bullish, 1 bearish, 1 mixed, 6 neutral · avg impact 4.0/10.Plus 12 press releases.
BULLISHANALYST-UPGRADE4/10
Argus Research double upgrade: Hold → Buy
Oct 1, 2026
BEARISHANALYST-DOWNGRADE2/10
Citigroup and Leerink Partners downgrade REGN to Neutral/Market Perform — PTs slashed to $700/$641; stock near PT levels
May 18, 2026
MIXEDANALYST-UPGRADE2/10
Benchmark upgrades REGN to Buy — PT $185 (-71.5%)
Jul 7, 2026
NEUTRALCLUSTER2/10
Two Regeneron insiders (EVP Commercial and a director) sold a total of $1.37M in open-market shares
Sep 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
fda
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemothe
Oct 1, 2026
fda
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment
Oct 1, 2026
contract
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-act
Sep 29, 2026
Clinical Trial
REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure
Phase Phase 2 — COMPLETED
Sep 28, 2026
Clinical Trial
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $15.99 | $14.53–$17.68 | 35.2% | -0.0% | 20↑ 0↓ | $4.5B | 21 |
| Next Q | $15.97 | $10.47–$23.62 | 39.6% | +2.3% | 19↑ 1↓ | $4.7B | 21 |
| Current FY | $54.77 | $43.42–$62.71 | 23.6% | +2.3% | 23↑ 0↓ | $17.0B | 27 |
| Next FY | $50.63 | $42.52–$57.25 | 15.4% | +0.5% | 5↑ 3↓ | $18.5B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $15.992 | — |
| 7d ago | $15.945 | +0.047 |
| 30d ago | $15.997 | -0.005 |
| 60d ago | $15.921 | +0.071 |
| 90d ago | $13.075 | +2.917 |
Institutional ownership
Which big funds own REGN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $44.5B total value (69,750,209 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, DODGE. Net buying activity: 35 institutions added/increased vs 15 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 9,113,506 | $5.7B | 12.8% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,629,759 | $4.1B | 9.3% | — |
| DODGE & COX | 4,871,137 | $3.0B | 6.8% | — |
| STATE STREET CORP | 4,834,688 | $3.0B | 6.8% | — |
| Invesco Ltd. | 3,940,665 | $2.5B | 5.5% | — |
| JPMORGAN CHASE & CO | 3,774,199 | $2.4B | 5.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,175,313 | $2.0B | 4.4% | ADD +84.5% |
| FRANKLIN RESOURCES INC | 2,771,839 | $1.7B | 3.9% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,625,810 | $1.6B | 3.7% | — |
| Nuveen, LLC | 2,019,974 | $1.3B | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 1,720,774 | 3,175,313 | +84.5% | $2.0B |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 1,837,459 | 1,270,087 | -30.9% | $792.0M |
| NORGES BANK | NEW | — | 1,172,808 | — | $731.3M |
| FMR LLC | TRIM | 1,518,192 | 831,964 | -45.2% | $518.8M |
| Capital World Investors | TRIM | 1,419,000 | 814,925 | -42.6% | $508.1M |
| FIRST TRUST ADVISORS LP | ADD | 346,855 | 547,132 | +57.7% | $341.2M |
| Robeco Institutional Asset Management B.V. | ADD | 348,787 | 460,602 | +32.1% | $287.2M |
| Man Group plc | ADD | 315,212 | 436,956 | +38.6% | $272.5M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 171,571 | 393,685 | +129.5% | $245.5M |
| Allianz Asset Management GmbH | ADD | 301,196 | 380,618 | +26.4% | $237.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 50 transactions. Net -$4.0M — $0.00 bought, $4.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | McCourt Marion | EVP Commercial | SELL | 1,131 | $857.39 | $969.7K |
| Sep 2, 2026 | McCourt Marion | EVP Commercial | SELL | 1,215 | $850.00 | $1.0M |
| Sep 2, 2026 | Guarini Kathryn | Director | EXERCISE | 400 | $719.37 | $287.7K |
| Sep 2, 2026 | Guarini Kathryn | Director | SELL | 400 | $850.00 | $340.0K |
| Aug 19, 2026 | LAROSA JOSEPH J | EVP General Counsel and Secret | EXERCISE | 12,282 | $381.92 | $4.7M |
| Aug 19, 2026 | LAROSA JOSEPH J | EVP General Counsel and Secret | TAX W/H | 9,019 | $830.15 | $7.5M |
| Aug 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | EXERCISE | 6,283 | $381.92 | $2.4M |
| Aug 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | TAX W/H | 4,599 | $813.47 | $3.7M |
| Aug 10, 2026 | Zoghbi Huda Y | Director | EXERCISE | 800 | $376.69 | $301.4K |
| Aug 10, 2026 | Zoghbi Huda Y | Director | SELL | 800 | $800.00 | $640.0K |
Congressional trades
REGN trades disclosed by members of Congress, with disclosure delay.
3 members · 4 buys / 0 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Regeneron Pharmaceuticals Inc | Aug 12, 2026(37d) |
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Regeneron Pharmaceuticals Inc | May 13, 2026(31d) |
| Mar 27, 2026 | Alan Armstrong | R | SENATE | BUY | $1,001 - $15,000 | Regeneron Pharmaceuticals Inc | Jul 22, 2026(117d) |
| Feb 12, 2026 | Julia Letlow | R | HOUSE | BUY | $1,001 - $15,000 | Regeneron Pharmaceuticals Inc | Mar 13, 2026(30d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for REGN.
Shares short
2,526,446
Settlement Sep 15, 2026
Change vs prior
-1.0%
Semi-monthly cycle
Days to cover
4.4
At avg daily volume
Of shares outstanding
≈2.5%
Estimate — not % of float
All REGN filing & press-release reports (26)
- Benchmark upgrades REGN to Buy — PT $185 (-71.5%)Jul 7, 2026
- Argus Research double upgrade: Hold → BuyOct 1, 2026
- Citigroup and Leerink Partners downgrade REGN to Neutral/Market Perform — PTs slashed to $700/$641; stock near PT levelsMay 18, 2026
- CLUSTER reportSep 4, 2026
- COURT-RULING reportAug 26, 2026
- PRESS-RELEASE reportAug 20, 2026
- CLUSTER reportAug 13, 2026
- COURT-RULING reportAug 12, 2026
- PRESS-RELEASE reportJul 30, 2026
- 8-K reportJul 30, 2026
- PRESS-RELEASE reportJul 27, 2026
- PRESS-RELEASE reportJul 17, 2026
- COURT-RULING reportJul 8, 2026
- 8-K reportJul 6, 2026
- PRESS-RELEASE reportJun 22, 2026
- PRESS-RELEASE reportMay 21, 2026
- PRESS-RELEASE reportMay 18, 2026
- PRESS-RELEASE reportMay 16, 2026
- PRESS-RELEASE reportMay 15, 2026
- DEFA14A reportApr 24, 2026
- PRESS-RELEASE reportApr 21, 2026
- 8-K reportApr 21, 2026
- PRESS-RELEASE reportApr 13, 2026
- PRESS-RELEASE reportApr 13, 2026
- COURT-RULING reportMar 30, 2026
- PRESS-RELEASE reportMar 25, 2026